share_log

Citigroup Upgrades Travere Therapeutics to Buy, Raises Price Target to $10

Benzinga ·  Dec 5, 2023 07:22

Citigroup analyst Carly Kenselaar upgrades Travere Therapeutics (NASDAQ:TVTX) from Neutral to Buy and raises the price target from $7 to $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment